- Hypertension:
- PO 80-320mg OD
- Heart failure with reduced ejection fraction (NYHA Class II-IV)
- Start with PO 80-160mg OD. Max 320mg/day
- Ventricular dysfunction following MI:
- Initially PO 20mg BD >12h post-MI, increased to 40 mg BD within 7 days. Increase to 160mg BD as tolerated. Max 320 mg/day
Tablet: 80mg, 160mg
- When used for heart failure with reduced ejection fraction, consider decreasing concomitant diuretic dose.
- There is decreased efficacy as monotherapy in Black patients when used for hypertension, therefore combination treatment preferred
Angiotensin II receptor (ARB) blocker
It blocks the binding of angiotensin II to its receptors; blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II. It does not cause persistent dry cough because it does not inhibit the breakdown of kinins.
- Increased BUN ≥50%
- Dizziness
- Postural hypotension
- Diarrhoea
- Arthralgia
- Fatigue
- Back pain
- Dizziness
- Hyperkalemia
- Hypersensitivity to ingredients
- Pregnancy; causes oligohydramnios in foetus resulting in foetus injury or death. Withdraw as soon as pregnancy is detected
- Patients < 6 years
- ACEIs
- Lithium
Drug Status
| Availability | Prescription only |
| Pregnancy | Category D |
| Breastfeeding | Not recommended |
| Schedule | Not controlled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Diovan | 80mg | Tablet | 28’s | Novartis Pharma | Novartis Kenya |
| Starval | 80mg | Tablet | 30’s | Sun Pharma | Sun Pharma |
| Starval | 160mg | Tablet | 30’s | Sun Pharma | Sun Pharma |
| Troval | 80mg | Tablet | 28’s | Delorbis Pharma | Europa Healthcare |
| Troval | 160mg | Tablet | 28’s | Delorbis Pharma | Europa Healthcare |
| Valsartan | 80mg | Tablet | 28’s | Novartis Kenya | Novartis Kenya |
| Valsartan | 160mg | Tablet | 28’s | Novartis Kenya | Novartis Kenya |